Has newer data and FDA label change changed how you discuss risk of NAION with the use of GLP-1 drugs?

With which patients taking GLP-1 drugs do you routinely discuss NAION risk?

• Patients without known NAION risk factors
• Patients with diabetes
• Patients with hypertension
• Patients who smoke
• Patients with sleep apnea
• Patients with crowded optic discs
• Patients with prior NAION
• I do not routinely discuss NAION risk
• Other